ArticleFrontiers in immunology2026
Predictors for the severity of acute aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorders: a prospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study aimed to investigate risk factors for disease severity in acute aquaporin-4 (AQP4) -IgG-seropositive neuromyelitis optica spectrum disorders (NMOSD) patients. Methods: This prospective cohort study enrolled 103 serum Aquaporin-4 Immunoglobulin G (AQP4-IgG)-positive NMOSD patients from the Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, between April 2022 and June 2025. Among them, 60 cases were in the acute phase and 43 in the remission phase. Additionally, 25 age-and sex-matched healthy controls (HCs) were included. Clinical characteristics of all participants were evaluated, and blood samples were collected for laboratory testing. The Expanded Disability Status Scale (EDSS) score was used to assess the severity of the disease. Receiver operating characteristic (ROC) curve analysis was performed using EDSS ≥ 4 as the definition of severe disability. Results: Our cohort study revealed significant differences (P < 0.05) in white blood cell (WBC) count, neutrophil (NEUT) count, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI), and serum complement levels among patients in the acute phase, those in the remission phase, and HCs. Multivariate regression analysis demonstrated that age (p = 0.01; OR = 0.06; 95% CI = 0.02-0.11), NLR (p = 0.018; OR = 0.24; 95% CI = 0.05-0.44), and complement 3 (C3) (p < 0.001; OR = 7.24; 95% CI = 3.77-10.72) were independent and significant risk factors for predicting the severity of disability (as assessed by the EDSS score) during the acute phase. Further ROC curve analysis demonstrated that C3 had strong predictive performance (AUC = 0.84), with high sensitivity and specificity at the optimal cut-off value. NLR showed limited overall discrimination (AUC = 0.62) but high specificity, suggesting a potential role as a rule-in marker. Age exhibited modest predictive value (AUC = 0.64), with an optimal cut-off of 45.5 years. Conclusion: Older age at onset, a higher NLR, and elevated serum C3 levels may predict greater disability in AQP4-IgG-positive NMOSD patients during the acute phase. Early identification of these predictive indicators could help guide initial treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.